By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Amsterdam Molecular Therapeutics (AMT) 

Meibergdreef 61

Amsterdam    1100 DA  The Netherlands
Phone: 31-0-20-5667394 Fax: 31-0-20-5667585


SEARCH JOBS


Industry
Pharmaceutical






Company News
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting 7/16/2012 10:04:24 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives Further Opinion on Glybera® Marketing Authorization Application 4/23/2012 7:04:47 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces Completion of Disposal of its Operations to uniQure B.V. and its Dissolution Becoming Effective 4/6/2012 10:01:17 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces Results of Extraordinary General Meeting 4/2/2012 10:27:37 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Publishes Positive Data from Glybera® 14 Week Study 3/28/2012 7:21:04 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives Request for Further Information From CHMP on Glybera(R) 2/21/2012 10:10:24 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces European Commission (EC) Delays Decision on Glybera® Marketing Authorisation and Requests Further Information From the CHMP 1/30/2012 7:05:45 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Receives US Orphan Designation for Hemophilia B Gene Therapy 1/4/2012 9:59:37 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces € 2.5 Million Equity Raise 1/3/2012 9:05:31 AM
Amsterdam Molecular Therapeutics (AMT) (RHP.DE) Announces Negative Equity Position 12/15/2011 10:42:30 AM
1234567
//-->